Acquisition expands NEXGEL’s health and wellness consumer product portfolio
Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins
Kenkoderm for the trailing twelve months is profitable and expected to be immediately accretive to
The Kenkoderm skincare line was originally developed by a dermatologist to provide alternative treatments for psoriasis that did not use steroids or biologics that often have side effects. Today, Kenkoderm has six stock keeping units (SKUs) including cream, salt soap, mud soap, shampoo, conditioner and multivitamin. The Kenkoderm products are sold primarily direct-to-consumer through e-commerce and Amazon, with a significant portion of revenue derived from subscription bundles. Kenkoderm, for the trailing twelve months is profitable and expected to be immediately accretive to
Transaction details
For details relating to the Kenkoderm transaction, please see the Company’s Form 8-K filed with the
About
About Kenkoderm
Kenkoderm was originally developed by a dermatologist for her husband, who suffered from psoriasis. He wanted an alternative treatment that did not use steroids or biologics that can often have side effects. After identifying that one source of the inflammation and flaring of psoriasis was caused by the skincare products he was using, the couple teamed up with other dermatologists to develop a skincare line focused on reducing symptoms associated with psoriasis. After realizing the significant positive impact of this product, a line of products containing ingredients that treat inflammation and breakouts was created. For more information, please visit www.kenkoderm.com.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended
Investor Contacts:
212.896.1254
valter@kcsa.com
Source:
2023 GlobeNewswire, Inc., source